Sana Zitouni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sana Zitouni has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amira Ayachi
Department of Gynecology and Obstetrics, Habib Bougatfa Hospital, Bizerte 7000, Tunisia
1 shared publication - Dorra Chaouachi
Laboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis ElManar, Tunis 1002, Tunisia
1 shared publication - Houyem Ouragini
Laboratory of Molecular and Cellular Hematology (HMC) , Institut Pasteur de Tunis , University of Tunis Elmanar , Tunis , Tunisia , pasteur.tn
1 shared publication - Imen Boudrigua
Laboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis ElManar, Tunis 1002, Tunisia
1 shared publication - Imen Kraiem
Laboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis ElManar, Tunis 1002, Tunisia
1 shared publication - Mechaal Mourali
Department of Gynecology and Obstetrics, Habib Bougatfa Hospital, Bizerte 7000, Tunisia
1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (4) , 107
Cord Blood-Based Neonatal Screening for Hemoglobinopathies in Northern Tunisia
Hemoglobinopathies represent a major public health concern in Tunisia. Although early diagnosis is essential, systemic neonatal screening has not yet been implemented at the national level. We conducted a screening study in Northern Tunisia (Bizerte region) using cord blood samples. Complete blood counts and hemoglobin analysis by capillary electrophoresis were performed. Samples showing abnormal profiles (HbBart’s, HbS, HbC, or HbA < 20%) underwent molecular testing. Correlations between hematological parameters, hemoglobin fractions, and β mutation types were assessed. Among 328 neonatal cord blood samples analyzed, we detected 3 silent α+-thalassemia, 6 β+-thalassemia traits, 3 β0-thalassemia traits, 7 HbS traits, 2 HbC traits, and 1 compound heterozygous for α+-thalassemia/HbC. No homozygous cases were identified. The heterozygous frequency was estimated at 1.2%, 2.7%, and 2.1% for α-thalassemia, β-thalassemia, and sickle cell disease, respectively. HbF levels were significantly associated with the β-thalassemia trait. This study represents the first hemoglobinopathy screening in Northern Tunisia using cord blood, highlighting the feasibility and reliability of this approach. While pilot programs have already been initiated in some regions, our findings reinforce the need for broader implementation to ensure early and accurate diagnosis across the country.
- 14 November 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (4) , 107
Open AccessCord Blood-Based Neonatal Screening for Hemoglobinopathies in Northern Tunisia
Hemoglobinopathies represent a major public health concern in Tunisia. Although early diagnosis is essential, systemic neonatal screening has not yet been implemented at the national level. We conducted a screening study in Northern Tunisia (Bizerte region) using cord blood samples. Complete blood counts and hemoglobin analysis by capillary electrophoresis were performed. Samples showing abnormal profiles (HbBart’s, HbS, HbC, or HbA < 20%) underwent molecular testing. Correlations between hematological parameters, hemoglobin fractions, and β mutation types were assessed. Among 328 neonatal cord blood samples analyzed, we detected 3 silent α+-thalassemia, 6 β+-thalassemia traits, 3 β0-thalassemia traits, 7 HbS traits, 2 HbC traits, and 1 compound heterozygous for α+-thalassemia/HbC. No homozygous cases were identified. The heterozygous frequency was estimated at 1.2%, 2.7%, and 2.1% for α-thalassemia, β-thalassemia, and sickle cell disease, respectively. HbF levels were significantly associated with the β-thalassemia trait. This study represents the first hemoglobinopathy screening in Northern Tunisia using cord blood, highlighting the feasibility and reliability of this approach. While pilot programs have already been initiated in some regions, our findings reinforce the need for broader implementation to ensure early and accurate diagnosis across the country.